A novel GLP-1 analog, a dimer of GLP-1 via covalent linkage by a lysine, prolongs the action of GLP-1 in the treatment of type 2 diabetes

[1]  A. Tahrani,et al.  Pharmacology and therapeutic implications of current drugs for type 2 diabetes mellitus , 2016, Nature Reviews Endocrinology.

[2]  M. Bednarek,et al.  Robust anti‐obesity and metabolic effects of a dual GLP‐1/glucagon receptor peptide agonist in rodents and non‐human primates , 2016, Diabetes, obesity & metabolism.

[3]  S. Grandy,et al.  Adherence to GLP-1 receptor agonist therapy administered by once-daily or once-weekly injection in patients with type 2 diabetes in Germany , 2016, Diabetes, metabolic syndrome and obesity : targets and therapy.

[4]  F. Reimann,et al.  Lipid derivatives activate GPR119 and trigger GLP-1 secretion in primary murine L-cells , 2016, Peptides.

[5]  T. Takamura,et al.  Once‐weekly glucagon‐like peptide‐1 receptor agonist dulaglutide is non‐inferior to once‐daily liraglutide and superior to placebo in Japanese patients with type 2 diabetes: a 26‐week randomized phase III study , 2015, Diabetes, obesity & metabolism.

[6]  D. Dutka,et al.  Glucagon-like peptide-1 protects against ischemic left ventricular dysfunction during hyperglycemia in patients with coronary artery disease and type 2 diabetes mellitus , 2015, Cardiovascular Diabetology.

[7]  J. Jelsing,et al.  The anti-diabetic effects of GLP-1-gastrin dual agonist ZP3022 in ZDF rats , 2015, Peptides.

[8]  Karen L Jones,et al.  Effects of exogenous glucagon-like peptide-1 on blood pressure, heart rate, gastric emptying, mesenteric blood flow and glycaemic responses to oral glucose in older individuals with normal glucose tolerance or type 2 diabetes , 2015, Diabetologia.

[9]  R. Seeley,et al.  Differences in acute anorectic effects of long-acting GLP-1 receptor agonists in rats , 2014, Peptides.

[10]  K. Khanal,et al.  Percentage of Hemoglobin A1C(HbA1c) as an Indicator of Pre-Diabetic Condition in Impaired Glucose Level Patients , 2014 .

[11]  D. Owens,et al.  Lixisenatide, a novel GLP‐1 receptor agonist: efficacy, safety and clinical implications for type 2 diabetes mellitus , 2014, Diabetes, obesity & metabolism.

[12]  J. Holst,et al.  GLP-1 amidation efficiency along the length of the intestine in mice, rats and pigs and in GLP-1 secreting cell lines , 2014, Peptides.

[13]  Zirong Wu,et al.  Glucagon-like peptide-1(1–37) can enhance blood glucose homeostasis in mice , 2012, Regulatory Peptides.

[14]  S. Stupp,et al.  Self-assembling glucagon-like peptide 1-mimetic peptide amphiphiles for enhanced activity and proliferation of insulin-secreting cells. , 2012, Acta biomaterialia.

[15]  J. Jendle,et al.  Glucagon-like peptide 1 (GLP-1) analogue combined with insulin reduces HbA1c and weight with low risk of hypoglycemia and high treatment satisfaction. , 2012, Primary care diabetes.

[16]  B. Nordén,et al.  Functionalization with C-terminal cysteine enhances transfection efficiency of cell-penetrating peptides through dimer formation. , 2012, Biochemical and biophysical research communications.

[17]  Y. Li,et al.  A novel GLP-1 analog exhibits potent utility in the treatment of type 2 diabetes with an extended half-life and efficient glucose clearance in vivo , 2011, Peptides.

[18]  C. Hölscher,et al.  Novel GLP‐1 mimetics developed to treat type 2 diabetes promote progenitor cell proliferation in the brain , 2011, Journal of neuroscience research.

[19]  Shuainan Liu,et al.  A novel GLP-1 analog, BPI3006, with potent DPP IV resistance and good glucoregulatory effect. , 2010, Biochemical and biophysical research communications.

[20]  Zirong Wu,et al.  Addition of a cysteine to glucagon-like peptide-1 (GLP-1) conjugates GLP-1 to albumin in serum and prolongs GLP-1 action in vivo , 2010, Regulatory Peptides.

[21]  N. Porksen,et al.  Engineering and characterization of the long‐acting glucagon‐like peptide‐1 analogue LY2189265, an Fc fusion protein , 2010, Diabetes/metabolism research and reviews.

[22]  D. Tew,et al.  Solid-phase synthesis of homodimeric peptides: preparation of covalently-linked dimers of amyloid beta peptide. , 2009, Chemical communications.

[23]  Michael W. Schwartz,et al.  Evidence that intestinal glucagon-like peptide-1 plays a physiological role in satiety. , 2009, Endocrinology.

[24]  M. Bush,et al.  Pharmacodynamics, pharmacokinetics, safety, and tolerability of albiglutide, a long-acting glucagon-like peptide-1 mimetic, in patients with type 2 diabetes. , 2008, The Journal of clinical endocrinology and metabolism.

[25]  Yinghe Hu,et al.  Mutated recombinant human glucagon-like peptide-1 protects SH-SY5Y cells from apoptosis induced by amyloid-β peptide (1–42) , 2008, Neuroscience Letters.

[26]  P. Halban,et al.  Increasing GLP-1–Induced β-Cell Proliferation by Silencing the Negative Regulators of Signaling cAMP Response Element Modulator-α and DUSP14 , 2008, Diabetes.

[27]  Manfred T Reetz,et al.  Iterative saturation mutagenesis (ISM) for rapid directed evolution of functional enzymes , 2007, Nature Protocols.

[28]  O. Schmitz,et al.  GLP-1 receptor agonists and DPP-4 inhibitors in the treatment of type 2 diabetes. , 2004, Hormone and metabolic research = Hormon- und Stoffwechselforschung = Hormones et metabolisme.

[29]  D. Drucker,et al.  A recombinant human glucagon-like peptide (GLP)-1-albumin protein (albugon) mimics peptidergic activation of GLP-1 receptor-dependent pathways coupled with satiety, gastrointestinal motility, and glucose homeostasis. , 2004, Diabetes.

[30]  R. Perfetti,et al.  GLP-1 inhibition of pancreatic islet cell apoptosis , 2004, Trends in Endocrinology & Metabolism.

[31]  A. Volonterio,et al.  Stereocontrolled synthesis of psi[CH(CF3)NH]gly-peptides. , 2003, Organic letters.

[32]  D. Drucker,et al.  Development and characterization of a glucagon-like peptide 1-albumin conjugate: the ability to activate the glucagon-like peptide 1 receptor in vivo. , 2003, Diabetes.

[33]  C. Deacon,et al.  The long-acting GLP-1 derivative NN2211 ameliorates glycemia and increases beta-cell mass in diabetic mice. , 2002, American journal of physiology. Endocrinology and metabolism.

[34]  J. Holst,et al.  Effect of 6-week course of glucagon-like peptide 1 on glycaemic control, insulin sensitivity, and β-cell function in type 2 diabetes: a parallel-group study , 2002, The Lancet.

[35]  J. W. Neidigh,et al.  Exendin-4 and glucagon-like-peptide-1: NMR structural comparisons in the solution and micelle-associated states. , 2001, Biochemistry.

[36]  J. Holst,et al.  GLP-1 slows solid gastric emptying and inhibits insulin, glucagon, and PYY release in humans. , 1999, American journal of physiology. Regulatory, integrative and comparative physiology.

[37]  B. Ahrén.  Glucagon‐like peptide‐1 (GLP‐1): A gut hormone of potential interest in the treatment of diabetes , 1998, BioEssays : news and reviews in molecular, cellular and developmental biology.

[38]  R. Zivin,et al.  Amino-terminal dimerization of an erythropoietin mimetic peptide results in increased erythropoietic activity. , 1997, Chemistry & biology.

[39]  R. Barrett,et al.  Increased potency of an erythropoietin peptide mimetic through covalent dimerization , 1997, Nature Biotechnology.

[40]  R. Cremlyn.  An introduction to organosulfur chemistry , 1996 .